Nanobiotix Expands Its Clinical Development in Head and Neck Cancer and Immuno-Oncology
- Written by ACN Newswire
Paris, France and Cambridge, Massachusetts, USA, Apr 4, 2017 - (ACN Newswire) - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the expansion and acceleration of its clinical development...
Read more: Nanobiotix Expands Its Clinical Development in Head and Neck Cancer and Immuno-Oncology